The complexity of cancer and the vast amount of experimental data available have made computeraided approaches necessary. Biomolecular modelling techniques are becoming increasingly easier to use, whereas hardware and software are becoming better and cheaper. Cross-talk between theoretical and experimental scientists dealing with cancer-research from a molecular approach, however, is still uncommon. This is in contrast to other fields, such as amyloid-related diseases, where molecular modelling studies are widely acknowledged. The aim of this review paper is therefore to expose some of the more common approaches in molecular modelling to cancer scientists in simple terms, illustrating success stories while also revealing the limitations of computational studies at the molecular level.
Introduction
necessitate the use of different methods. In general, the more accurate the method at hand, the more time Example application: You know the structures of two proteins and have some information of their com-plex, e.g., from cross-linking experiments. Brownian dynamics can then be used to follow on complex 157 formation, for example when more than one binding mode is possible.
159
Brownian dynamics (BD) simulations in biomedicine are most often used to follow on the formation 160 of complexes, e.g., between two or more proteins. Such systems are too large and evolve too slowly 161 to be studied directly by MD, especially when several binding modes are possible. Therefore, more 162 approximate methods must be used to infer how the complex is formed. MD simulations can be used at 163 a later stage to discriminate between several potential complexes.
164
In the context of biomolecular BD simulations, the forces are extracted from the electrostatic po- 
Modelling based on quantum chemistry 172
Strengths: Accuracy and scope -can deal with processes that involve covalent bond making and break-173 ing or excited states of molecules that cannot be studied by more approximate methods.
174
Limitations: Slow, difficult to master, available only for short timescales and small systems.
175
Example application: You want to understand how a certain carcinogen interacts with nucleic acid bases. it can offer a better accuracy compared with molecular dynamics and other methods that rely on energy 179 functions that do not involve quantum-mechanics, and can deal with processes involving bond-breaking 180 and formation. Unfortunately, the computational cost of employing quantum chemistry programs can be 181 prohibitive. Moreover, the underlying principles (quantum mechanics) may be non-intuitive and difficult 182 to grasp by non-experts. To make things even more complicated, quantum chemists use a highly specific 183 jargon that make it even more difficult to follow the relevant publications compared with other molecular 184 modelling methods.
185
Due to the high computational cost, QM calculations are very rarely performed on full-size proteins, 186 although this situation is likely to change because methods to deal with large molecules, e.g., [20, 21] , are 187 being actively developed . Instead, a model of the system of interest (e.g., a catalytic site of an enzyme) 188 is constructed by taking into account a subset of atoms that directly participate in the reaction. The rest 189 of the system is either ignored or approximated by use of faster methods (e.g., quantum mechanics / 
Ab initio molecular dynamics 197
Strengths: Modelling dynamics processes as molecular dynamics with the accuracy offered by quantum 198 chemistry.
199
Limitations: Limited to very small systems (tens of atoms) and very short time scales (10 −11 s).
200
Example application: Following on an enzymatic reaction using a model system based on the active-site Limitations: As slow as quantum chemistry.
217
Example application: Following on an enzymatic reaction, taking into account all of the protein residues, 218 not just the catalytic site.
220
Quantum mechanics / molecular mechanics (QM/MM) methods treat part of the system (e.g., the 221 catalytic site of an enzyme and a substrate) quantum-mechanically and the rest in more approximate 
Normal Mode Analysis

230
Strengths: Simple, fast and relatively easy to do -a quick way to get a glimpse on the dynamics at atomic 231 resolution without running a simulation.
232
Limitations: No correlation to timescales, not as broad and accurate as MD.
233
Example application: You study a large protein with several domains and want to learn how the domains 234 move one with respect to the other, because this is relevant to that protein's function.
236
In normal mode analysis the system (e.g., a protein or a biomolecular complex) is assumed to be in 237 equilibrium, while it still undergoes some motions. These motions are modelled as harmonic (similar to 238 a bead on a spring). Low frequency modes represent collective motions that involve large parts of the 239 system (e.g., two protein domains moving towards and away from each other), whereas high frequency trajectories. There are, however, several drawbacks of the method. First, motions of proteins are not 245 entirely harmonic [32] . Second, the system needs a proper preparation before performing normal mode analysis rigorously (its potential energy must be brought very close to minimum), which is often a difficult regions rather than a defined three dimensional structure [34] . Moreover, proteins and peptides often Limitations: Can only work when a structure of a related protein is known.
270
Example application: You want to simulate a human protein, whose structure is not available, based on 271 the structure of the same (or a similar) protein but from another organism.
273
Homology modelling (also known as comparative or template-based modelling) is based on the notion 274 that evolutionary conservation in sequence is correlated with conservation in structure. In other words,
275
proteins that are similar in sequence are also similar in structure (whereas the latter is not always true).
276
Thus, given a template protein with a known structure, which is somewhat similar in sequence to another 277 protein whose structure is sought after, a computer program is used to thread the sequence of the protein 278 with the unknown structure onto the template. Modern homology modelling software enables the use of 279 multiple templates (for example, where a protein has two domains and each has a different homologue).
280
The higher the sequence identity between a modelled protein and a template, the higher the accuracy 281 of the model. Although many factors can contribute to the success of modelling by homology, it is 282 generally said that proteins that have >50% sequence identity to the target can be modelled accurately, 
Modelling of protein complexes
317
The approach to generating a structural model of a complex involving a protein and another biological 318 macromolecule depends on the existing data. If the structure of a similar complex is known, homology 319 modelling can be used. Otherwise, one should first obtain structures or models of the participants. Then, 320 a model can be generated by employing a program designated for the task. As is common in the field, 321 several research groups have generated webservers that are aimed at modelling protein complexes, and 322 a list of those is given in Table A .8. Typically, the servers produce a list of potential structures, sorted 323 according to the underlying algorithm. It is eventually up to the user to select the model that makes most 324 sense.
325
To generate models of protein complexes, servers employ different approaches. One of these is 326 surface complementarity, where the proteins or macromolecules that interact are assumed to complement 327 each other structurally (i.e., one can fit onto the other, similar to two pieces of a puzzle). The resulting 
Protein-drug interaction prediction
Identifying drug-like molecules that can bind to and inhibit the function of proteins is one of the most 336 important objectives of computational medicinal chemistry. Kinases and various proteases in particular 337 are interesting cancer-related targets of computer-aided drug design. The most straightforward approach 338 is to use a structure of the target protein bound to an inhibitor and identify molecules that are structurally 339 similar to that inhibitor. These candidate molecules are then fitted into the binding sites, and the com-340 plexes are refined and studied by use of computer simulation methods such as molecular dynamics as a 341 mean of validation. In many cases, however, this relatively straightforward approach does not yield any 342 improvements or has already been exhausted, and it is necessary to identify chemically novel molecules, 343 which may be more promising as leads to medication. This is when molecular docking approaches are 344 employed. MET (adsorption, distribution, metabolism, excretion and toxicity), which can be modelled separately.
349
Not suitable for discriminating between similar compounds that bind the same target.
350
Example application: Discovery of novel kinase inhibitors [37] . 
362
Owing to the complexity of the task and the large amount of computational resources needed for lig-363 and docking into proteins, it is more common to use a traditional computer program than an online server, 364 although some servers do exist. Docking servers and programs are described in Tables A.9 
Simplified models that can yield biological insights
369
Modelling every atom in the molecule comes with a cost, and is not always meaningful: consider a 370 complex of several proteins, large and small, that has a regulatory effect in the cell. It is hardly plausible 371 that the regulatory effect is influenced by every amino acid side chain. In other cases, it is currently not 372 possible to accurately model the conformation of a protein, because the protein has some unstructured 373 regions (large flexible regions without any regular secondary structure). A prominent example of the 374 latter case is p53, which has both folded and intrinsically disordered domains. Finally, we may need to 375 deal with a protein with a known structure, but which undergoes a slow transition that cannot be modelled 376 by atomistic methods because it takes too long. All of these cases necessitate the use of simplified models, 377 often in conjugation with some of the methods that are used also (or predominantly) in atomistic studies 378 such as MD simulations (section 2.1.1) or normal mode analysis (section 2.1.6). involve changes in the secondary structure, and it is difficult to model drug molecules and cofactors such 402 as heme. In addition, the simulation timescales do not correspond well with the experiment.
403
Example application: Simulations of large proteins or biomolecular complexes.
405
In coarse-grained simulations, molecules are represented by a collection of beads rather then atoms.
406
Each bead represents several atoms (e.g., an amino acid side chain) or residues. Alternatively, in phe- Third, water molecules are usually presented in a relatively crude way and not simulated explicitly,
419
providing an additional speed-up factor. Thus, coarse-grained simulations can be used to study processes 420 that cannot be followed by use of atomistic simulations because they are too slow or systems that cannot 421 be handled because they are too large.
422
The gain in speed of coarse-grained simulations is countered by some drawbacks. The most obvi-423 ous limitation of such simulations is that atomistic details are lost. Moreover, temporal and energetic 424 estimations are also less accurate than those provided by an atomistic approach. Another caveat is the 425 availability of coarse-grained representations and force fields. Methods for coarse-graining exist for pro-tein residues and some types of lipids but generally not for ligands, cofactors, etc.
427
A hierarchical (or multiscale) approach may be used to overcome the first limitation. The system is 428 studied at the more simplistic coarse-grained level first. Then, some parts of the trajectory are highlighted 
476
To understand its mechanism of action, the compound was docked to the crystal structure of tubulin 477 bound to colchicine. Molecular dynamics simulations were then used to identify the protein residues that 
Autoactivation of ERK2
495 Extracellular signal-regulated kinase 2 (ERK2) is a kinase involved in the MAPK signalling pathway.
496
The enzyme is activated by cooperative phosphorylation events at Tyr 185 and then Thr 183 , which result 497 in a conformational transition. Mutation of certain ERK2 residues leads to autophosphorylation and 498 therefore to autoactivation. Barr and co-workers have studied the active and inactive forms of ERK2 499 and several mutants that cause autoactivation [50] . By use of molecular dynamics simulations, they 500 have analysed the differences between the dynamics of mutants and wt proteins, and showed that the 501 mutations do not mimic the active conformation. Rather, they lead to domain closure that is likely to 502 promote autoactivation. Several mutations had been suggested to render autoactivation based on this 503 study, and all but one were verified experimentally. protein drug). The wild type (wt) protein and four promising mutants, as well as one mutant that was experimentally found to be less active (although it is not degraded by AEP) were then subject to exten-514 sive analysis by molecular dynamics simulations. The computer-aided protein engineering process was 515 successful according to enzymatic and cell-toxicity assays. Furthermore, the authors could selectively in- that is generated by a certain p53 mutation [55] . An identified compound bound to p53 and made it more 531 stable, effectively mimicking a rescue mutation. 
Atomistic structures of yttrium-containing glasses for cancer therapy
533
The radioactive isotope 90 Y of the rare earth metal yttrium is used in cancer therapy due to its cy- as hepatic neoplasia. To reduce side effects due to the toxicity of 90 Y, the glass should not release yt-538 trium into the blood. Unfortunately, it is difficult to analyse the local structure near the yttrium atom by 539 experimental measurements. On the other hand, the periodic structure of the clinically important yttrium-540 alumino-silicate (YAS) glass is advantageous from a computational point of view, because a relatively 541 small model can be studied due to the periodicity of the system (long term interactions are handled by 542 an algorithm that replicates the small model in all directions). Moreover, the system is stable enough so 543 that short-term quantum-mechanics based calculations could be performed and represent its equilibrium 544 properties (something that cannot be assumed in the case of macromolecules). Accordingly, Christie and
545
Tilocca have studied YAS glass by ab-initio molecular dynamics simulations [56] . The study elucidated 546 the atomistic structure of YAS glass; future studies can deal with calculations of the energy needed to 547 remove an yttrium atom from the glass or with the design of more stable yttrium binding compounds.
548
Larger samples and perhaps more approximate methods will be necessary to achieve these aims. The 
Therapeutic aspects
577
Molecular modelling is already being extensively used in the development of novel cancer drugs, as 578 exemplified in the previous sections. The specific interactions between an existing drug and its target can 579 be modelled (as outlined in section 2.3.1), and modelling can be used in the generation of novel and more 580 effective compounds (as exemplified for L-asparaginase in section 3.5).
581
One setting that is particularly interesting in the perspective of targeted therapeutics is the possibility 582 of predicting which compounds will be active in the presence of resistance mutations. Targeted thera-583 pies are being increasingly used in cancer treatment, and the mechanisms of action are often based on 584 the inhibition of a single protein, such as BCR-ABL, KIT, EGFR, RAF or ALK. However, since these 585 proteins are all part of complex signalling networks, modifying the activity of one pathway member will 586 inevitably result in changed expression levels or activity of other proteins in the pathway. There is also an 587 apparent redundancy of many important signalling networks in cancer that leads to alternate signalling if 588 one protein is inhibited. Thus, in almost all cases the disease becomes resistant to the targeted therapy, 589 and much effort is being devoted to the identification of resistance mechanisms.
590
A common resistance mechanism is the occurrence of a secondary mutation in the target protein, 591 leading to decreased sensitivity towards the inhibitor. One example is the secondary resistance mutation 592 T790M in the EGFR gene, which confers resistance to the EGFR inhibitors gefitinib and erlotinib in 593 non-small cell lung cancer. Shortly after its identification it was suggested, based on structural modelling, 594 that the introduction of a bulky methionine residue in position 790, which is located at the entrance to 
Conclusions and outlook
616
One of the consequences of the post-genomic era is the realisation that biological macromolecules 617 are much more complex than thought before. The straightforward relation sequence-structure-function is to attend some of the (too few) courses that explain the methods as well as the underlying theories.
628
Realising the pros and cons of the approach is necessary to be able to validate its potential use in the 629 field, and we have tried to provide some information that would enable cancer researchers to study the 630 matter more closely. In our view, many of the tools described in this paper have the potential to become 631 a useful part in the cancer-research arsenal, as they already are in other fields. We therefore have little 632 doubt that molecular modelling approaches will become widely used for cancer research in the years 633 to come, in particular for the design of drugs and other treatments and the understanding of biological 634 networks.
635
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